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in vivo assessment of tumour proliferation. Most importantly, [18F]FLT does not seem to
be accumulating in inflammatory processes, as seen in [18F]-fludeoxyglucose, the most
commonly used PET tracer for assessment of cell metabolism. [18F]FLT could therefore pro-
vide additional information about the tumour biology before, during and after treatment. This
systematic review focuses on the use of [18F]FLT-PET tumour uptake values as a measure of
tumour response to therapeutic interventions. The clinical studies which evaluated the role of
[18F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence
linking [18F]FLT-PET tumour uptake values with clinical outcome is evaluated.
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Positron emission tomography (PET) has become an
essential component of cancer imaging and management
of cancer patients over the past 10e15 years. PET im-
aging is a physiological imaging technique that depends
on tumour pathophysiology and metabolic processes [1].
The distinctive properties of PET imaging agents (e.g.
[18F]-fludeoxyglucose [[18F]FDG] reflecting glucose
metabolism, 30-deoxy-30-18F-fluorothymidine [[18F]FLT]
being a marker for tumour cell proliferation and various
other tracers for imaging of other cancer hallmarks)
allow spatial detection and localisation of the patho-
physiological processes [2,3]. Therefore, information
rendered from PET images can serve as an indicator of
response to treatment which affect these processes.
Thus, PET imaging agents can serve many unique pur-
poses, such as patient stratification, eligibility confir-
mation, disease progression, response assessment and
prediction of clinical outcomes.
Response assessment in solid tumours is usually
performed using size criteria derived from computed
tomography (CT) scans [4]. Vigorous discussion has
confronted the use of anatomic assessments alone,
primarily as it may take several weeks to notice any
reduction in tumour size. Moreover, only morpholog-
ical information can be attained, and this may not be
suitable to assess early treatment response. Further-
more, novel targeted therapies may not even lead to
tumour shrinkage despite having a beneficial effect on
patient outcome. These limitations made clinicians
concentrate more on functional and molecular imaging
techniques such as PET imaging using specific tumour
metabolic tracers [5]. Measurement of functional im-
aging biomarkers compared to mere morphological
evaluation may allow for more accurate evaluation of
various cancer types and their development through
time.
The most commonly used PET tracer in oncology is
[18F]FDG for measuring tumour glucose metabolism [6].
[18F]FDG is a glucose analogue and is phosphorylated
by hexokinase, but cannot undergo further metabolism
in the glycolytic pathway [7]. Hence, the degree of [18F]
FDG uptake detected by the PET scanner reflects the
level of glucose metabolism. The specificity of [18F]
FDG-PET may decrease in the presence of [18F]FDG-
avid treatment-induced inflammation surrounding the
tumour. This occurrence may hamper the interpretation
of [18F]FDG-PET scans as [18F]FDG uptake in acti-
vated inflammatory cells may lead to overestimation of
the percentage viable tumour cells and depreciating the
feasibility of observing an early metabolic response [8].
To improve the accuracy of early PET assessment
and the accuracy of target delineation, [18F]FLT has
been introduced for imaging tumour cell proliferation
[1]. [18F]FLT is monophosphorylated by thymidine ki-
nase 1 (TK1), which leads to intracellular trapping.Since the activity of TK1 is elevated during the S phase
of the cell cycle, [18F]FLT-PET uptake reflects tumour
cell proliferation. Hence, there is a good probability that
persistent [18F]FLT-PET uptake after the first cycle of
treatment would mean that the drug either did not reach
its target or was ineffective. Thus, [18F]FLT-PET is very
likely to become a ‘drug terminator’ helping drug de-
velopers to eliminate ineffective compounds in the early
phase clinical trials [5].
Quantifying tumour proliferation using [18F]FLT-
PET has several advantages: primarily, it is non-
invasive procedure, [18F]FLT-PET generates three-
dimensional tumour images and multiple tumour sites
can be measured simultaneously and repeatedly [9].
Moreover, [18F]FLT-PET is capable of evaluating whole
tumour proliferation heterogeneity, which is not
possible in biopsy specimens, and it is clinically feasible
in day-to-day practice [10]. Therefore, the purpose of
this review is to investigate the clinical value of [18F]
FLT-PET proliferative imaging for prediction of
response to treatment. This will further allow clinicians
to better understand the tumour metabolic
processes and thereby select specific drug agents or
treatment strategies which precisely targets key meta-
bolic pathways.
2. Materials and methods
2.1. Search strategy
To identify all relevant publications, we performed
systematic searches in the bibliographic databases
EMBASE.com and the Cochrane Library (via Wiley)
from inception to 1st September 2015. Search terms
included controlled terms from EMtree in EMBASE.
com as well as free-text terms. We used free-text terms
only in the Cochrane Library (see supplemental data).
Search terms expressing ‘FLT-PET’ were used in com-
bination with search terms comprising ‘neoplasms’. The
references of the identified articles were searched for
relevant publications.
2.2. Selection process
Two reviewers (VRB and GMK) independently
screened all potentially relevant titles and abstracts for
eligibility. If necessary, the full-text article was checked
for the eligibility criteria. Differences in judgement were
resolved through a consensus procedure.
Studies were included if they met the following criteria:
(i) The study investigated the performance of [18F]FLT-
PET/CT or PET for evaluating treatment response in
oncological patients;
(ii) Patients underwent chemotherapy, chemoradiotherapy
or radiotherapy; and
(iii) Clinical outcome was assessed.
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(i) Animal or in vitro studies;
(ii) Studies on investigational drugs;
(iii) Not available in full text or not written in English; and
(iv) Certain publication types: reviews, editorials, letters,
legal cases, interviews, case reports, and comments.
3. Results
3.1. Search results
The literature search generated a total of 967 references:
949 in EMBASE.com and 18 in the Cochrane Library.
After removing duplicates of references that were
selected from more than one database, 935 references
remained. The flow chart of the search and selection
process is presented in Fig. 1. Out of 935, only 35 were
considered as eligible. Table 1 includes a summary of
clinical studies and their outcome in various tumour
types based on [18F]FLT-PET/CT proliferative imaging.Fig. 1. Flowchart of the search and3.2. Systemic therapy
Recently, [18F]FLT-PET is drawing attention as an early
predictor of tumour response. The predictive value of
pre-treatment [18F]FLT-PET imaging in aggressive non-
Hodgkin’s lymphoma (NHL) cancer patients (n Z 62)
treated with standard cyclophosphamide, doxorubicin,
vincristine and prednisolone with rituximab (R-CHOP)
regimen was evaluated by Herrmann et al. [11]. Pre-
treatment [18F]FLT-PET scans showed a lower mean
standardised uptake value (SUVmean) for those
achieving complete response compared with non-
complete response (p Z 0.049). Another study by this
group (n Z 54) [12] showed that reduction of [18F]FLT
SUVmean/mean maximum standardised uptake values
(SUVmax) 1 week after the start R-CHOP was signifi-
cantly larger in patients reaching complete response
(p < 0.006). Change in SUV was also inversely corre-
lated with survival and showed a hazard ratio of 0.65
per point increment of [18F]FLT SUVmean. These re-
sults are in accordance with findings from Lee et al. [13]selection procedure of studies.
Table 1
Summary of clinical studies and their outcomes in various tumour types based on [18F]FLT-PET proliferative imaging.
No. of
patients
Tumour
type
Treatment type Clinical study Purpose Results Conclusion(s) Reference
20 Breast
cancer
CTx Relationship between change in
[18F]FLT-PET uptake and clinical
response.
To establish whether early changes
in [18F]FLT-PET can predict
clinical response to docetaxel
therapy in breast cancer.
Docetaxel treatment resulted in a
significant decrease in [18F]FLT
uptake for both SUVmax and
SUVmean at 60 min. Decrease in
[18F]FLT uptake was significantly
larger in responders compared to
non-responders (40.2% versus
10.5% resp.). A >20% reduction
SUVmean was associated with
target lesion size changes and
response after three cycles (0.85
sensitivity and 0.80 specificity).
Changes in [18F]FLT-PET early
after initiating docetaxel
chemotherapy are associated with
target lesion response mid-therapy.
[22]
14 Breast
cancer
CTx and
hormonal
therapy
Change in [18F]FLT uptake and
correlation with response to
treatment
To determine the whether [18F]
FLT-PET is useful in the
monitoring of breast cancer
therapy, as compared with [18F]
FDG-PET and to assess the value
of [18F]FLT-PET in predicting
long-term clinical outcome.
Change in [18F]FLT uptake after
one cycle of chemotherapy are
correlates with late changes in
tumour size and change in CA
27.29 tumour marker levels
(respectively p Z 0.01 and
p Z 0.001).
[18F]FLT uptake after one cycle of
chemotherapy is correlated with
changes in tumour size and tumour
marker levels. Therefore, [18F]FLT
may be useful in predicting long
term clinical outcome of breast
cancer.
[23]
13 Breast
cancer
CTx Relationship between change in
[18F]FLT parameters and
treatment response.
To define whether [18F]FLT-PET
can be used to quantify early
response of breast cancer to
chemotherapy.
Decreases in Ki and SUV (at
90 min) 1 week after treatment
discriminated between clinical
response and stable disease
(p Z 0.022 for both parameters).
Responding lesions had an average
decrease in [18F]FLT-PET of 41.3%
and 52.9% for SUV90 and Ki,
respectively. In non-responding
lesions, there was an average
increase in both variables.
[18F]FLT-PET is able to
distinguish patients with stable
disease and those with CR/PR 1-
week post-treatment.
[2]
53 HNSCC RT or CHRT Correlation between baseline [18F]
FLT uptake and response to
treatment.
To assess the value of pre-
treatment [18F]FLT uptake in the
prediction of treatment response
and comparison to [18F]FDG-PET.
Baseline [18F]FLT SUVmax, MTV
and TLG are strongly correlated to
LRC and OS in univariate analysis.
Moreover, TLG was an
independent factor of LRC and
SUVmax and MTV of OS in
multivariate analyses. [18F]FLT in
general performed better than [18F]
FDG-PET.
Baseline [18F]FLT uptake
correlates well with clinical
outcome and might be a prognostic
factor in treatment of HNSCC.
[39]
48 HNSCC RT or CHRT Association between [18F]FLT
parameters and clinical outcome.
To monitor early treatment
response using [18F]FLT-PET in
HNSCC and evaluating
relationship between [18F]FLT-
PET parameters (SUVmax9,
Significant decrease in [18F]FLT-
PET uptake was noticed between
successive scans. Decrease in
SUVmax(9) 45% during the first 2
weeks of treatment is associated
Favourable long-term outcome
correlated significantly with greater
decrease in [18F]FLT-PET uptake
in the second week of treatment.
[33]
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GTV50%, and GTVSBR) and clinical
outcome.
with better 3-year DFS 88% (95%
CI: 75e100) versus 63% (95% CI:
41e85), p Z 0.035.
46 HNSCC CHRT Relationship between tumour
proliferation volume and clinical
outcome.
To compare [18F]FLT-PET
segmentation methods (PVVIS,
PVRTL, PVFLAB and PVW&C) for
evaluating tumour proliferative
volume and its relation to clinical
outcome.
Baseline PVVIS correlated best with
PVFLAB and GTVCT (0.77,
p < 0.001). A reduction in PVFLAB
above the median (7.39 cm3)
between the pre-treatment scan
and the fourth week scan of CHRT
was predictive of a better 4-year
DFS (90  9.5% versus
53  17.6%, p Z 0.04).
PVFLAB PET segmentation method
performed best in delineating
tumour proliferative volume and
determining clinical outcome.
[32]
32 HNSCC CHRT and
surgery
The predictive potential of baseline
[18F]FLT for short-term clinical
outcome.
To assess the correlation of
baseline [18F]FLT-PET metrics
with loco-regional control and OS.
Baseline MTV, TLP and SUVpeak
are associated with logo-regional
control and OS (p < 0.05).
Moreover, MTV and TLP was
significantly lower in responders to
therapy compared to non-
responders.
Baseline [18F]FLT-PET has
potential to predict clinical
outcome when MTV, TLP or
SUVpeak are used.
[40]
28 HNSCC CHRT Early response evaluation by [18F]
FLT-PET in HNSCC undergoing
CHRT.
To evaluate the value of [18F]FLT-
PET in assessing locoregional
clinical outcome of CHRT.
[18F]FLT-PET uptake decreased
gradually during RT than [18F]
FDG-PET uptake. The specificity
and overall accuracy of [18F]FLT-
PET were significantly better than
[18F]FDG-PET both during and
after treatment (p < 0.0001).
Patient group with residual [18F]
FLT-PET uptake after treatment is
associated with poor local tumour
control when compared with no
accumulation group (45% versus
97.5%, p < 0.0001).
[18F]FLT-PET uptake has the
potential to predict treatment
outcome and identify patients at a
risk of local failure.
[34]
20 HNSCC RT and CHRT Value of [18F]FLT-PET uptake in
HNSCC patients.
To evaluate correlation between
[18F]FLT-PET uptake and Ki-67
index and if [18F]FLT-PET uptake
has prognostic value as determined
by a correlation to patient survival.
No correlation was observed
between [18F]FLT-PET uptake and
Ki-67 index, but significant inverse
correlation was observed between
[18F]FLT-PET uptake (r Z 0.53;
p < 0.05) and patient survival.
High [18F]FLT-PET uptake is
associated with adverse prognosis.
[35]
10 HNSCC RT Value of [18F]FLT-PET/CT in
oropharyngeal cancer patients.
To monitor early tumour response
based on [18F]FLT-PET/CT scans
and to determine the feasibility of
personalised adaptive radiotherapy
to chemoradioresistant
proliferative sub-volumes identified
by [18F]FLT-PET.
[18F]FLT-PETdefined SUVmax and
SUVmean decreased significantly
just 1 week after start of treatment.
However, GTV defined on CT
(GTVCT) decreased only after third
week of treatment. Dose escalation
to [18F]FLT-PET defined active
proliferative volumes (GTV80%
threshold) is technically feasible.
[18F]FLT-PET defined tumour
functional changes precede CT
defined volumetric changes and
therefore suitable for early tumour
response assessment.
[28]
(continued on next page)
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Table 1 (continued )
No. of
patients
Tumour
type
Treatment type Clinical study Purpose Results Conclusion(s) Reference
50 NSCLC TKI Relationship between change in
[18F]FLT-PET uptake and clinical
outcome in NSCLC.
To determine whether patients with
[18F]FLT-PET response on day 14
and 56 of erlotinib treatment had
longer PFS and OS than patients
without PET response.
Nine of 50 (18%) [18F]FLT-
evaluable patients had PMR at day
14. Four (7.8%) showed PR by day
56 CT; three of them had PMRs by
day 14 [18F]FLT-PET. Day 14 and
day 56 PMRs by [18F]FLT were
associated with improved PFS. But
[18F]FLT-PET PMR was not
associated with improved OS
compared with [18F]FLT-PET non-
responders.
[18F]FLT uptake 2 and 6 weeks
after start of treatment show a
correlation with PFS but not with
OS. Furthermore, [18F]FLT-PET
scans identify more patients with
PMR and more patients with
progression than standard CT
assessment.
[19]
40 NSCLC Erlotinib
(if progression
CTx or RT)
Correlation between baseline [18F]
FLT uptake and clinical outcome.
Assessing the prognostic value of
baseline [18F]FLT-PET uptake in
patients with metastatic NSCLC
prior to systemic therapy with first-
line erlotinib.
Low [18F]FLT uptake at baseline
(SUVmax < 3.0) was associated
with longer survival (p Z 0.027).
However, [18F]FLT-PET was not
shown to be an independent
prognostic factor in multivariate
analysis (p Z 0.077). SUVmax in
baseline [18F]FLT-PET shows an
association with response to
erlotinib treatment (p Z 0.043).
This was not translated into
prolonged PFS in patients with low
[18F]FLT uptake.
[18F]FLT-PET baseline uptake is
significantly associated with longer
survival and response to treatment
in univariate analysis and,
however, was not shown to be an
independent prognostic factor in
multivariate analysis in contrast to
[18F]FDG.
[14]
40 NSCLC TKI Clinical outcome and relationship
with treatment induced changes in
[18F]FLT-PET parameters.
To evaluate the clinical benefit of
first-line treatment with erlotinib
using different quantitative
parameters for [18F]FLT-PET in
advanced NSCLC patients.
Metabolic [18F]FLT-PET response
measured as proposed by the
PERCIST guideline (1.0) 1 week
after start of erlotinib showed a
significantly longer PFS
independent of the SUV used. This
was not shown for response
measurement after 6 weeks of
treatment.
Early [18F]FLT-PET
measurements are correlated with
PFS regardless of the method used
for SUV calculation.
[15]
34 NSCLC TKI Treatment induced change in [18F]
FLT-parameters and correlation
with clinical outcome.
To study the accuracy of [18F]FLT-
PET after 1 week of first-line
erlotinib therapy for early
prediction of non-progression after
6 weeks of therapy in patients with
advanced NSCLC.
Four of six patients with an early
[18F]FLT response (30%
reduction in SUVpeak), all having
an absolute reduction of 0.4,
were non-progressive after 6 weeks
of treatment (p Z 0.15). A
significantly prolonged PFS was
observed in patients with an early
[18F]FLT response (6.0 versus 1.6
months; p Z 0.04.) Late [18F]FLT
response was not associated with
improved PFS. Early and late [18F]
Early [18F]FLT response was
associated with PFS but not with
OS or non-progression after 6
weeks of treatment with erlotinib.
[17]
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FLT responses were not associated
with prolonged OS (OS,
16.0 versus 4.9 months, p Z 0.3).
28 NSCLC TKI Predicting clinical outcome using
[18F]FLT imaging at baseline, after
start of treatment and using
treatment induced changes in [18F]
FLT-PET.
To assess the value of
TLP determined by [18F]FLT-PET
for prediction of response and
clinical outcome in patients with
advanced NSCLC treated with
erlotinib.
Patients with a metabolic response
(>20% reduction) measured by
early TLP show a significantly
better PFS than metabolically non-
responders. Furthermore, patients
with lower absolute early and late
residual TLP levels had a
significantly prolonged PFS. In
contrast, absolute baseline TLG
and TLP levels showed no
significant association with PFS.
Reduction in TLP of >20% and
absolute residual TLP levels under
erlotinib treatment emerged as
predictive factors for PFS in
patients with NSCLC.
[18]
28 NSCLC TKI Change in [18F]FLT-PET after
treatment and relation with clinical
response.
To evaluate the usefulness of [18F]
FLT-PET for predicting response
and clinical outcome of gefitinib
therapy in patients with
adenocarcinoma of the lung.
Pre-treatment SUVmax did not
differ between responders and non-
responders on CT evaluation. At 7
d after the initiation of therapy, the
percent changes in SUVmax were
significantly different (p < 0.001).
Change in [18F]FLT uptake
has high positive and negative
predictive values. TTP is
significantly longer in [18F]FLT-
PET responders than non-
responders (p Z 0.004). The
median OS for patients with and
without [18F]FLT-PET response
was not significantly different
(p Z 0.26).
[18F]FLT-PET is correlated to TTP
and can predict response to TKI
early after start of treatment in
non-smokers with NSCLC. The
change in tumour SUVmax seems
to have a promising predictive
value.
[16]
20 NSCLC RT Change in [18F]FLT-PET/CT
during carbon ion radiotherapy.
To evaluate the clinical value of
[18F]FLT-PET/CT in lung cancer
patients receiving carbon ion
radiotherapy.
Tumour [18F]FLT-PET uptake
decreased significantly after
treatment (p < 0.001). However,
radiation pneumonitis hampered
precise [18F]FLT-PET uptake
evaluation. Patients who developed
recurrence or who died of lung
cancer during follow-up had high
pre-treatment [18F]FLT-PET
uptake than that of patients who
did not (p Z 0.008, p Z 0.007).
Also in patients with SUVmax
<3.7 showed significantly better
prognosis (pZ O.003 for PFS and
p Z 0.002 for DFS).
Pre-treatment [18F]FLT-PET
SUVmax carries prognostic value
and may contribute to decision
making on the treatment approach.
[30]
(continued on next page)
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Table 1 (continued )
No. of
patients
Tumour
type
Treatment type Clinical study Purpose Results Conclusion(s) Reference
14 NSCLC TKI Relationship between [18F]FLT-
PET uptake and clinical outcome.
To study the diagnostic efficacy of
[18F]-FLT for response evaluation
following 3 weeks of treatment
with EGFR-TKI in NSCLC
patients.
[18F]FLT SULpeak values show no
significant correlation with PFS
(p Z 0.2) and OS (p Z 0.07).
Using a ROC curve responders
were defined as a decrease of 22%
in [18F]FLT SULpeak and a
decrease of 0.7 in absolute values.
This gave a sensitivity and
specificity of 100%.
No correlation was found between
[18F]FLT SULpeak and OS and
PFS in patients treated with
EGFR-TKI for 3 weeks.
[20]
11 NSCLC CTx Value of [18F]FLT-PET in
NSCLC.
To evaluate the effect of
pemetrexed induced TS inhibition
on [18F]FLT-PET scan 4 h after
pemetrexed administration in stage
IV NSCLC patients.
All patients showed decreased
deoxyuridine levels after
pemetrexed administration
indicating pemetrexed induced TS
inhibition. However, no significant
correlation was observed between
[18F]FLT-PET uptake and clinical
outcome. Also, baseline was not
predictive for tumour response
(p Z 0.86).
A non-systematic change in [18F]
FLT-PET uptake was observed
4 h after pemetrexed
administration. However, the
association between [18F]FLT-PET
uptake and TTP, OS or tumour
response was not significant.
[21]
7 NSCLC RT Change in [18F]FLT-PET uptake
due to RT alone.
To evaluate whether [18F]FLT-
PET changes occur early in
response to radiotherapy without
concurrent chemotherapy.
Primary tumours SUVmean
reproducibility (SD 8.9%) is better
than SUVmax reproducibility (SD
12.6%). Primary tumour SUVmean
decreased significantly by 25%
after 5e11 radiotherapy fractions
in the absence of significant
volumetric change (p Z 0.0001).
Locoregional tumour control was
found to be associated with
primary tumour SUVmax at
radiotherapy (HR: 2.3 CI: 1.06
e5.0, p Z 0.03) but not with
SUVmax at baseline (HR: 1.46, CI:
0.97e2.18, p Z 0.068).
[18F]FLT-PET is a valuable clinical
tool to report early on radiation
response and to intensify treatment
for patients with increased [18F]
FLT-PET uptake to further
improve locoregional tumour
control.
[31]
62 DLBCL CTx Relationship between baseline [18F]
FLT-PET and treatment response
and clinical outcome.
To correlate the initial [18F]FLT
uptake with the clinical outcome of
patients with DLBCL treated with
standard R-CHOP.
Baseline SUVmean was
significantly lower in CR groups
(SUVmean: 7.1; range: 1.0e18.2)
than non-CR groups (partial
response and progressive disease,
SUVmean 9.4, range: 1.2e20.4,
p Z 0.049). Also, significant
positive correlation was observed
between [18F]FLT-PET SUVmean
and IPI risk groups (p < 0.001).
No correlation between baseline
[18F]FLT uptake and OS.
Baseline [18F]FLT uptake is
correlated with treatment response
and high [18F]FLT uptake is a
negative predictor of response to
R-CHOP treatment in DLBCL.
[11]
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61 NHL CTx Relationship between change in
[18F]FLT parameters and clinical
outcome in NHL.
To evaluate the prognostic value of
early [18F]FLT-PET in patients
with NHL.
Patients who were defined as [18F]
FLT-PET positive (SUVmax >
1.86) after one cycle and at the end
of chemotherapy or [18F]FLT-PET
positive after one cycle and
negative at the end of treatment
had significant worse 5-year PFS
and OS rates (p < 0.001) then early
PET-negative patients.
Multivariable analyses shows that
the prognostic value of interim
[18F]FLT-PET positivity by
remained significant after
adjustment with other prognostic
factors (PFS and OS, p Z 0.009
and p Z 0.014, respectively).
[18F]FLT-PET positivity after one
cycle of chemotherapy has a
significant correlation with worse
PFS and OS compared to PET-
[18F]FLT negative patients.
[13]
54 DLBCL CTx Treatment induced change in [18F]
FLT uptake and correlation with
treatment response.
To prospectively assess if [18F]FLT
uptake and the decrement of [18F]
FLT uptake after 1 week of
immunochemotherapy are suitable
to predict response and clinical
outcome in patients with DLBCL.
SUVmean and SUVmax decrease 1
week after chemotherapy was
significantly higher in patients
achieving complete response.
Martingale-residual and Cox
proportional hazard analyses
showed a significant monotonous
decrease of mortality risk with
increasing change in SUV. The
corresponding estimated hazard
ratios per point increment of
SUVmean and SUVmax were 0.65
(p Z 0.001) and 0.60 (p Z 0.002),
respectively.
Change in [18F]FLT-PET 1 week
after the start of R-CHOP
chemotherapy is correlated with
clinical response and survival.
[12]
22 NHL CTx Correlation of baseline [18F]FLT-
PET and treatment induced change
with treatment response.
To evaluate [18F]FLT-PET for
early monitoring response of high-
grade NHL to treatment with
chemotherapy with or without
rituximab (R-CHOP/CHOP).
There was no statistically
significant difference between
initial [18F]FLT-uptake in patients
with PR or CR, as indicated by the
CT scan. All patients responding to
chemotherapy showed significant
reduction of [18F]FLT uptake.
There was a significant difference
in [18F]FLT retention between
patients reaching PR versus CR at
the end of therapy.
[18F]FLT-PET was significantly
correlated to PR and CR and
seems to be promising for early
evaluation of therapy in
lymphoma.
[10]
8 AML CTx Correlation between [18F]FLT
parameters and treatment
response.
To investigate the use of [18F]FLT-
PET for assessment of early
treatment response in patients with
AML.
[18F]FLT uptake in bone marrow
was significantly lower in patients
with CR compared to those with
RD after 2 weeks of chemotherapy
(p < 0.001). These results were
independent of time of assessment.
[18F]FLT-PET may serve as an
early biomarker of response to
treatment in AML.
[41]
(continued on next page)
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Table 1 (continued )
No. of
patients
Tumour
type
Treatment type Clinical study Purpose Results Conclusion(s) Reference
18 mCRC CTx Early prediction of response and
clinical outcome using change in
[18F]FLT parameters after
treatment.
To evaluate [18F]FLT-PET for
early prediction anatomic response
and survival outcomes in patients
with mCRC receiving FOLFOX.
[18F]FLT-PET SUVmax was
increased compared with baseline
values both in responders and non-
responders on day 2 after start of
treatment (p Z 0.043 and
p < 0.001, respectively). A
SUVmax increase of 45.8% on
day 2 (low [18F]FLT flare)
optimally differentiated between
responders and non-responders.
Patients with low [18F]FLT flare on
day 2 tended to have longer
survivals than patients with high
flare (2-year overall survival rate,
77.8% versus 44.4%, p Z 0.051).
Responders showed a decreased
SUVmax compared to baseline on
day 5 (p Z 0.043). No significant
differences were found in PFS or
OS.
The height of the [18F]FLT flare
observed during 5-FU infusion was
correlated with treatment response
in patients with mCRC. The degree
of [18F]-FLT flare was also
associated with poor clinical
outcome of patients who receive
continues infusion of 5-FUebased
chemotherapy.
[27]
14 Rectal
cancer
CHRT [18F]FLT-PET as a predictor of
outcome in rectal cancer patients.
To evaluate whether baseline and
early during treatment [18F]FLT-
PET uptake of tumour is a
predictor of outcome in locally
advanced rectal cancer patients.
[18F]FLT-PET uptake decreased
significantly after therapy from
baseline. Low [18F]FLT-PET
uptake during treatment and
change in [18F]FLT-PET uptake
60% were predictors of DFS
(p < 0.05). However, pre-treatment
[18F]FLT-PET uptake did not
correlate with DFS. Also, no
significant correlation was found
between DSUV and
histopathological tumour
regression.
Early [18F]FLT-PET uptake
(SUVmax < 2.2) during treatment
predicts DFS in locally advanced
rectal cancer patients.
[37]
45 Gastric
cancer
CTx Correlation of [18F]FLT
parameters at baseline, during
treatment and change in [18F]FLT
parameters with clinical outcome
and response.
To assess whether [18F]FLT-PET
can improve the predictive
potential of molecular imaging for
assessing response to neoadjuvant
therapy in gastric cancer compared
with [18F]FDG-PET.
No significant correlation between
clinical response and baseline SUV,
absolute SUV after 2 weeks of
treatment or change in SUV after
treatment was found. Univariate
Cox regression analysis revealed
significant prognostic impact for
survival only for [18F]FLT
SUVmean day 14 (p Z 0.048).
Multivariate Cox regression
analysis [18F]FLT SUVmean day
[18F]FLT uptake 2 weeks after
initiation of therapy was shown to
be the only imaging parameter with
significant prognostic impact.
Neither [18F]FLT-PET nor [18F]
FDG-PET were correlated with
histopathological or clinical
response.
[42]
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14 as the only significant
prognostic factors (p Z 0.002).
20 Pancreatic
cancer
CTx Treatment induced change in [18F]
FLT uptake and correlation with
clinical outcome and response to
treatment.
To investigate early response
assessment using [18F]FLT PET/
CT in pancreatic cancer patients.
A significant correlation was found
between [18F]FLT-PET response
and response assessment on
RECIST after three months of
treatment (p Z 0.04). An increase
in SUVmax of 12% optimally
differentiated non-responders and,
however, was not predictive for
PFS and OS (p > 0.5).
[18F]FLT-PET could be used to
assess response to chemotherapy in
pancreatic cancer. No correlation
was found with clinical outcome
and, however, larger studies are
needed since this study was not
powered to evaluate PFS and OS.
[43]
34 Oesophageal
cancer
RT and CHRT Correlation of baseline [18F]FLT
uptake and change after treatment
with clinical outcome.
To evaluate the prognostic value of
treatment response assessed with
[18F]FLT-PET in oesophageal
cancer and compare it with [18F]
FDG-PET.
A decrease in [18F]FLT-PET
SUVmax of >60% 4 weeks after
start of treatment showed the
strongest correlation with better 2-
year PFS and LRC (pZ 0.025 and
0.046, respectively). [18F]FLT
uptake had a stronger correlation
with clinical-outcome in patients
receiving CHRT compared to RT
alone. No association with OS was
found for any of the parameters.
Follow-up using interim [18F]FLT-
PET could be used for prediction
of PFS and LRC in oesophageal
cancer and seems to be superior to
[18F]FDG-PET.
[36]
9 Oesophageal
cancer
CTx Early tumour response evaluation
by [18F]FLT-PET in resectable
oesophageal cancer patients.
To determine the feasibility of [18F]
FLT-PET in predicting early
tumour response after induction
chemotherapy followed by
concurrent CHRT in resectable
oesophageal cancer patients.
[18F]FLT-PET SUVmax decreased
significantly after the induction
chemotherapy (median 7.7e2.8,
p Z 0.0012) in responders while
little decrease was observed in the
non-responder (median 4.9e4.4).
Eventually, the non-responder was
found with liver metastases during
surgery.
Change in primary tumour
SUVmax might be a good
parameter for the prediction of
concurrent CHRT response in
oesophageal cancer patients. Most
importantly, [18F]FLT-PET may
recommend earlier alterations of
treatment strategies in non-
responders.
[26]
30 Glioma CTx and
bevacizumab
Early prediction of clinical
outcome using treatment induced
change in [18F]FLT uptake.
To assess the value of [18F]FLT for
early outcome predictions in
patients treated for recurrent
glioma.
Change in [18F]FLT uptake 2 and 6
weeks after start of treatment is
predictive of PFS and OS in
univariate and multivariate
analyses. Survival was 3.3 times as
long in responders (>25%
decrease). Change 6 weeks after
start of treatment showed the
strongest correlation (p Z 0.001).
Change in [18F]FLT-PET is
correlated to PFS and OS, and,
therefore could be used as an
predictive tool to asses clinical
outcome in recurrent glioma.
[25]
19 Glioma CTx and
bevacizumab
Change in [18F]FLT uptake and
association with clinical outcome.
To determine if early and/or late
[18F]FLT-PET can predict
outcome and treatment response in
patients treated for recurrent
glioma.
Both early and late change in [18F]
FLT uptake after the start of
treatment was predictive for overall
survival. Patients showing a 25%
reduction in [18F]FLT uptake
tended to have prolonged OS and
PFS. [18F]FLT at any time point
did not predict clinical outcome.
Reduction in [18F]FLT-PET
uptake 1e2 as well as 6 weeks after
start of treatment correlated well
with clinical outcome.
[24]
(continued on next page)
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Table 1 (continued )
No. of
patients
Tumour
type
Treatment type Clinical study Purpose Results Conclusion(s) Reference
13 Mucosal
melanoma
RT Prediction of clinical outcome
using baseline [18F]FLT-PET and
change after during carbon ion
radiotherapy.
To determine the predictive and
prognostic value of [18F]FLT-PET
for response to treatment in
patients with mucosal malignant
melanoma.
Pre-treatment SUVmax 4.3 and
5.0 are prognostic factors for
better OS and metastasis-free
survival, respectively. Change in
[18F]FLT uptake of 35% 4 weeks
after start of treatment only
showed a correlation with LRC.
Post-treatment SUVmax did not
correlate with clinical outcome.
[18F]FLT-PET might be useful to
predict clinical outcome in mucosal
melanoma patients treated with
carbon ion radiotherapy.
[44]
11 Germ cell
Tumours
CTx Early response monitoring using
[18F]FLT uptake and prediction of
viable residual tumour in patients
with metastatic GCT.
To assess the diagnostic efficacy of
[18F]FLT PET compared to [18F]
FDG-PET for early response
monitoring and prediction of
residual viable tumour after
chemotherapy of metastatic GCT.
In responders and non-responders,
the mean SUV of [18F]FLT
decreased by 58% and 48%,
respectively, (p Z 0.5). At the end
of therapy, these were decreased to
68% and 65%, respectively
(p Z 0.8). The sensitivity,
specificity, positive and negative
predictive value for detection of
viable tumour after the first cycle
of chemotherapy were 60%, 80%,
75%, and 67%, respectively. After
the end of chemotherapy, these
were 0%, 100%, 0%, and 50%.
[18F]FLT cannot improve
prediction of viable residual
tumour in patients with metastatic
GCT compared to [18F]FDG,
because of the low negative
predictive value. Prediction of
response cannot be replaced by
early [18F]FLT and [18F]FDG
response evaluation.
[45]
Abbreviations: [18F]FLT Z [18F]-fluorothymidine; FDG Z [18F]-fluorodeoxyglucose; PET Z positron emission tomography; HNSCC Z head and neck squamous cell carcinomas; NSCLC Z non-
small-cell lung carcinoma; DLBCLZ diffuse large B-cell lymphoma; NHLZ non-Hodgkin’s lymphoma; mCRCZ metastasised colorectal cancer; GCTZ germ cell tumour; AMLZ acute myeloid
leukaemia; CHRT Z chemoradiotherapy; RT Z radiotherapy; CTx Z chemotherapy; C/E Z cisplatin/etopside; C/P Z carboplatin/paclitaxel; EGFR Z epidermal growth factor receptor;
TKIZ tyrosine kinase inhibitor; CHOPZ cyclophosphamide, doxorubicin, vincristine and prednisolone; R-CHOPZ CHOP with rituximab; FOLFOXZ folinic acid, fluorouracil and oxaliplatin; 5-
FU Z fluorouracil; TS Z thymidylate synthase; PVVIS Z proliferative tumour volume delineated visually; PVRTL Z proliferative tumour volume delineated using a background-subtracted relative
threshold level; PVFLABZ proliferative tumour volume delineated using a fuzzy locally adaptive Bayesian algorithm ; PVW&CZ proliferative tumour volume delineated using a gradient-based method
using the watershed transform algorithm and hierarchical clustering analysis; GTVCTZ gross tumour volumes visually delineated on computed tomographic images; GTV50%Z gross tumour volumes
delineated using a 50% isocontour of the maximum signal intensity; GTVSBR Z gross tumour volumes delineated using signal-to-background ratio; SUV Z standardised uptake value;
SUVmaxZ maximum standardised uptake value; SUVmeanZ mean standardised uptake value; SUVmax(9)Z mean maximum standardised uptake values for the hottest voxel in the tumour and its
eight surrounding voxels in one transversal slice; TLG = total lesion glycolysis; TLPZ tumour lesion proliferation; SULpeakZ SUV corrected for lean body mass; MTVZ metabolic tumour volume
DFS Z disease-free survival; PFS Z progression-free survival; TTP Z time to progression; CR Z complete remission; PR Z partial response; PMR Z partial metabolic response; OS Z overall
survival; HRZ hazard ratio; CIZ confidence interval; LRCZ locoregional tumour control; SDZ standard deviation; CAZ cancer antigen; IPIZ International Prognostic Index; ROCZ receiver
operating characteristic.
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V.R. Bollineni et al. / European Journal of Cancer 55 (2016) 81e97 93who also studied prognostic value of [18F]FLT in 61
NHL patients.
Similar studies were performed in non-small-cell lung
cancer (NSCLC) patients treated with tyrosine kinase
inhibitors (TKIs) (Fig. 2). Baseline [18F]FLT-PET
SUVmax <3.0 proved to be a prognostic indicator
(hazard ratio [HR] 2.2, p Z 0.027), correlating signifi-
cantly with response to treatment and prolonged sur-
vival in patients with metastatic NSCLC treated with
erlotinib (n Z 40) [14]. Kahraman et al. [15] evaluated
the clinical benefit of first-line treatment with erlotinib
using [18F]FLT-PET in 40 patients with advanced
NSCLC. [18F]FLT-PET response was measured as
proposed by the PERCIST (1.0) guidelines. [18F]FLT-
PET scans 1 week after start of erlotinib treatment
predicted progression-free survival (PFS) showing po-
tential for response prediction. These results are sup-
ported by data of three other studies showing that
change in [18F]FLT-PET, 1 week after start of erlotinib
therapy correlated with PFS (HR: 0.30, p Z 0.04)
[16e18]. This correlation was also found when response
evaluation is performed after 2 weeks, but data obtained
3 or 6 weeks after start of TKI treatment were ambig-
uous, indicating the importance of an adequate time
interval for scanning [17,19,20].
Regardless of timing, change in [18F]FLT uptake
showed no correlation with overall survival (OS)
(p > 0.07) in NSCLC patients, this in contrast to [18F]
FLT response evaluation in NHL [16,17,19e21]. This
discrepancy might be due to differences in effect size of
chemotherapy and TKI treatment; hence, larger studies
might be needed to demonstrate correlation between
treatment with TKI and OS. In many of the studies onFig. 2. An 18F-fluorothymidine positron emission tomography/
computed tomography scan of a non-small-cell lung cancer patient
before (A), after 7 d (B) and 26 d (C) after start of tyrosine kinase
inhibitor treatment.NSCLC, performance of [18F]FLT-PET was also
compared to [18F]FDG-PET, which often yielded better
correlations with PFS and OS [14]. Therefore, the
additional value of [18F]FLT-PET for evaluation of
treatment response in NSCLC might be limited.
Subsequently, several other studies reported on the
utility of [18F]FLT-PET in prediction of early tumour
response for other tumour types. Contractor et al. [22]
performed dynamic scans at baseline and 2 weeks after
the first or second cycle of docetaxel in 20 breast cancer
patients. The decrease in [18F]FLT-PET uptake
observed at 60 min was significantly larger for re-
sponders than non-responders (40.2% versus 10.5%) and
authors concluded that change in [18F]FLT-PET early
after initiating docetaxel is associated with target lesion
response mid-therapy. Moreover, another study showed
that change in [18F]FLT-PET uptake after one cycle
chemotherapy could predict tumour response in breast
cancer patients (n Z 14) [23]. The decline of [18F]FLT-
PET tumour uptake 1 week after start of chemo-
therapy also showed a correlation with clinical response
(n Z 13) [2].
[18F]FLT-PET has also been studied in patients with
recurrent high-grade glioma treated with bevacizumab
and irinotecan [24]. [18F]FLT-PET scans acquired at 2
weeks after start of treatment found that SUVmean
significantly predicted overall survival (p Z 0.006).
Similar results were reported by others, confirming the
value of [18F]FLT-PET tumour uptake in predicting
tumour response to chemotherapy [25].
Furthermore, a study was performed to prospectively
evaluate [18F]FLT-PET as imaging biomarker to deter-
mine the early impact of induction chemotherapy before
concurrent chemoradiotherapy (CHRT) in resectable
oesophageal cancer patients (nZ 9) [26]. Eight patients
with complete or partial response showed a decrease in
[18F]FLT-PET uptake values after induction chemo-
therapy (median: 57.1%), while the non-responder
showed little change in [18F]FLT-PET uptake (median:
10.2%). This study suggests that early decrease in [18F]
FLT-PET uptake after induction chemotherapy might
be useful for predicting treatment response in these
patients.
In all former studies, a decrease of [18F]FLT uptake
after start of therapy was correlated to better response.
This decrease is interpreted as a decrease in proliferation
rate and demand of thymidine. However, treatment with
drugs interfering with endogenous thymidine synthesis
(e.g. 5-fluorouracil) may result in a flare of [18F]FLT
uptake due to an increase in TK1 activity. In 18 patients
with metastasised colorectal cancer, Hong et al. [27]
observed an inverse correlation between the height of
the flare and response to treatment. Patients with low
flares also tended to have longer survival. This suggests
that the degree of [18F]FLT flare might be useful to
predict the outcome of patients who undergo 5-FU-based
chemotherapy; however, this has to be further explored.
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Serial [18F]FLT-PET scans have been performed in pa-
tients with oropharyngeal cancer by Troost et al. [28].
Ten patients underwent three consecutive [18F]FLT-
PET scans, at baseline and 2 and 4 weeks after start of
radiotherapy to assess early tumour response, tumour
heterogeneity and identifying tumour sub-volumes with
active proliferation. SUVmax and SUVmean decreased
significantly as early as 1 week after start of treatment
and continued to decrease up to the fourth week of
treatment (SUVmean: 4.7  1.6, 2.0  0.9 and 1.3  0.2;
p < 0.001). The decrease in [18F]FLT uptake was more
than two-fold in the initial phase of treatment and a
further two-fold decrease in the fourth week after start
of treatment. These results suggest that [18F]FLT-PET
can assess treatment response much earlier than [18F]
FDG-PET. Likewise, another group also showed a sig-
nificant decrease in [18F]FLT-PET uptake after 10 Gy of
radiotherapy in head and neck squamous cell carcinoma
(HNSCC) patients [29]. Troost et al. [28] observed a
significant decrease in gross tumour volume delineated
on CT (GTVCT) only at the end of treatment (GTVCT in
cubic centimetres: 12.7  9.5, 11.1  8.8 and 5.0  4.7).
Hence, [18F]FLT-PET uptake precedes CT tumour
response and is therefore valuable for early treatment
response. Furthermore, it appears that residual [18F]
FLT-PET tumour sub-volumes within the tumour at 2
weeks after start of treatment should receive higher ra-
diation doses to improve locoregional tumour control
(LRC) and consequently OS. In this regard, a well-
demarcated proliferative area at [18F]FLT-PET 2 weeks
after start of RT seems to be appropriate and can be
treated with spatially conformed doses by precisely
targeting tumour proliferation.
The clinical value of [18F]FLT-PET/CT imaging before
and 3months after carbon ion radiotherapywas evaluated
by Saga et al. [30] in NSCLC patients (nZ 20). No cor-
relation between SUVmax after treatment or treatment
induced change and local recurrence, development of
metastasis or survivalwas demonstrated.Yet, they showed
that allNSCLCpatients who developed recurrence orwho
died of lung cancer during follow-up had higher pre-
treatment [18F]FLT-PET uptake compared to patients
who did not (pZ 0.008, pZ 0.007). These results suggest
the possibility of using [18F]FLT-PET as tool for patient
stratification and risk assessment; however, this requires
validation in larger cohorts.Trigonis et al. [31] showed that
SUVmean reproducibility (standard deviation [SD]: 8.9%)
in primary tumours was better than SUVmax reproduc-
ibility (SD: 12.6%) inNSCLC patients (nZ 16). They also
showed that primary tumour SUVmean decreased signif-
icantly by 25% (pZ 0.001) after 5e11 fractions of RT in
the absence of tumour morphological change. However,
conforming the previous results, this decrease was corre-
lated neither to OS nor to LRC rates.3.4. Chemoradiotherapy
Changes in an imaging biomarker to evaluate patho-
logical and physiological response can play a vital role
in recognising an appropriate therapeutic agent. For
example, the association between elevated tumour pro-
liferation and increased incidence of tumour growth and
resistance to treatment provides an underlying rationale
for enhanced radiation dose delivery to the proliferative
volume of the tumour [17]. Therefore, accurate delin-
eation of the proliferative tumour volume (PV) is pivotal
for delivering radiotherapy based on the repopulation
response and subsequently clinical outcome.
To evaluate proliferative volume of the tumour and
its relation to clinical outcome in HNSCC, Arens et al.
[32] compared different [18F]FLT-PET segmentation
methods: 1) PVVIS: visual delineation, 2) PVRTL: relative
threshold level, 3) PVFLAB: fuzzy locally adaptive
Bayesian, and 4) PVW&C: watershed transform and hi-
erarchical clustering. Forty-six patients treated with
CHRT underwent [18F]FLT-PET/CT at baseline and in
the second and fourth weeks of treatment. A reduction
in PVFLAB above the median (7.39 cm
3) between the pre-
treatment scan and the fourth week scan was predictive
of a better 4-year disease-free survival (DFS) (90  9.5%
versus 53  17.6%, pZ 0.04). The PVFLAB obtained at 2
and 4 weeks after start of treatment showed no corre-
lation with LRC and OS.
In another study, Hoeben et al. [33] evaluated oper-
ator-dependent (PET-segmented GTV using visual
delineation [GTVVIS] and mean SUVmax uptake values
for the hottest voxel in the tumour and its eight sur-
rounding voxels in one transverse plane [SUVmax(9)])
and operator-independent (50% isocontour of the
SUVmax [GTV50%] and signal-to-background ratio
[GTVSBR]) segmentation methods to delineate tumour
volumes on the sequential [18F]FLT-PET/CT scans in
stage IIeIV HNSCC patients (n Z 48). A decrease in
SUVmax(9) 45% and a GTVVIS decrease median
during the first 2 weeks of treatment is associated with
better 3-year DFS 88% (95% confidence interval [CI]:
75e100) versus 63% (95% CI: 41e85). Operator-inde-
pendent segmentation methods could not accurately
define tumour areas during treatment due to fading
signal-to-background ratios. Overall, an early decrease
in [18F]FLT-PET uptake (second week) during treat-
ment is associated with favourable treatment outcome.
Recently, Kishino et al. [34] assessed early treatment
response evaluation by [18F]FLT-PET in HNSCC pa-
tients. In this study, all patients (nZ 28) underwent [18F]
FLT and [18F]FDG-PET scans at baseline, 4 weeks after
the start of CHRT and 5 weeks after the completion of
treatment. The specificity and accuracy of [18F]FLT-PET
scans were significantly higher than [18F]FDG-PET
scans both during and after radiotherapy. Again poten-
tial was demonstrated in HNSCC for predicting outcome
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between no-accumulation and residual accumulation
groups for post-treatment [18F]FLT-PET scans (HR: 25.6,
p < 0.001). [18F]FLT and [18F]FDG scans were also per-
formed to assess radiotherapy or CHRT treatment
response in HNSCC patients (nZ 20) by Linecker et al.
[35]. Although no correlation was observed between Ki-
67-positive cells and [18F]FLT-PET uptake, a significant
correlation was found between [18F]FLT-PET uptake and
OS (rZ 0.53, p < 0.05).
These results combined suggest that [18F]FLT-PET is
a promising tool for early response assessment of
radiotherapy in HNSCC and may differentiate lesions
from radiotherapy-induced inflammation more effec-
tively than [18F]FDG-PET. Comparable results are seen
in oesophageal cancer patients (nZ 34) where PFS and
LRC are significantly correlated with change in [18F]
FLT uptake 4 weeks after start of RT or CHRT [36].
However, both tumour types require further studies to
elucidate the connection of [18F]FLT-PET uptake with
survival in larger patient population.
The value of [18F]FLT-PET imaging for monitoring
tumour response to pre-operative CHRT in patients
with locally advanced rectal cancer (n Z 14) was also
evaluated [37]. Significant reduction in tumour [18F]
FLT-PET uptake was observed 2 weeks after start of
neoadjuvant CHRT (p < 0.0001). Authors demon-
strated that low [18F]FLT-PET uptake during treatment
(SUVmax <2.2) and high percentage change in [18F]
FLT-PET uptake (60%) significantly predicted DFS
(p < 0.005) for all uptake metrics, respectively. How-
ever, their results did not correlate with histopatholog-
ical response. Similar results were reported in another
study (n Z 10) where [18F]FLT-PET uptake showed a
significant decrease between baseline and 2 weeks after
start of treatment (4.2  1.0 to 2.9  0.6,
e28.6  10.7%, pZ 0.005), with an additional decrease
at the pre-operative PET scan (1.09  0.4,
e54.7  7.6%, pZ 0.005) [38]. Yet, change in [18F]FLT
uptake also did not correlate with pathological response.
It is thought that the lack of the correlation is related to
inadequate tracer delivery due to poor blood supply
secondary to radiotherapy. Next, due to lack of statis-
tical power in both studies, caution is necessary when
interpreting these results. Additional studies are
required to establish the value of [18F]FLT-PET imaging
in rectal cancer.
3.5. Limitations
The studies described above have several limitations.
Firstly, all studies are single-centre observational studies
with small sample sizes. Due to these small sample sizes,
studies might be underpowered to confirm correlations
with clinical outcome and treatment response and cor-
rect interpretation of results could be impaired. Sec-
ondly, many studies defined thresholds retrospectively.Therefore, to validate these thresholds and to further
confirm the impact of [18F]FLT as imaging biomarker of
treatment response, interventional studies with larger
patient populations are needed.
Finally, imaging procedures have to be standardised
to obtain comparable results within different studies. Up
to now, several imaging protocols are used with differ-
ences in uptake time, time per bed position and acqui-
sition methods which could influence quantitative
analyses and decrease comparability of results.
4. Conclusion
Overall, [18F]FLT-PET seems to be a good predictor of
early response to systemic-, radio- and concurrent che-
moradiotherapy. PFS and DFS show good correlations
with [18F]FLT uptake; however, the correlation with
overall survival is less consistent. Moreover, it is of great
importance to perform the response assessment at an
adequate time interval. If change in [18F]FLT response is
assessed too soon or too late after start of treatment, the
discriminative power of [18F]FLT-PET might be
compromised. Furthermore, [18F]FLT-PET might be
developed into a tool for guiding individualisation of
treatment strategies as it is able to detect active prolif-
erative tumour sub-volumes and could provide addi-
tional information on chemoradioresistant areas.
However, up to now, mostly observational studies have
been performed and larger interventional studies
assessing the clinical impact of [18F]FLT as imaging
biomarker are required.
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